Coherus BioSciences Launches an On Body Injector for the Administration of Udenyca (biosimiolar, pegfilgrastim) to Treat Non-Myeloid Malignancies
Shots:
- The US FDA approved Udenyca Onbody earlier in Dec 2023, as an OBI device to administer Udenyca, a biosimilar of pegfilgrastim. The company has launched Udenyca in the US market for the treatment of patients with non-myeloid malignancies
- Udencya is a leukocyte growth factor indicated to be administered the day after CT to lower the rate of infection caused by febrile neutropenia and increase survival in patients exposed to myelosuppressive doses of radiation
- The Udenyca Onbody is comprised of a five-minute injection time, an indicator, a status light, an auditory signal, and a needle that automatically retracts after the administration
Ref: Coherus | Image: Coherus
Related Post:- Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
